317 related articles for article (PubMed ID: 26358483)
1. [Vortioxetine: a new antidepressant to treat depressive episodes].
Colle R; Corruble E
Encephale; 2016 Feb; 42(1):48-58. PubMed ID: 26358483
[TBL] [Abstract][Full Text] [Related]
2. Vortioxetine for the treatment of major depressive disorder.
Tritschler L; Felice D; Colle R; Guilloux JP; Corruble E; Gardier AM; David DJ
Expert Rev Clin Pharmacol; 2014 Nov; 7(6):731-45. PubMed ID: 25166025
[TBL] [Abstract][Full Text] [Related]
3. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data.
Sanchez C; Asin KE; Artigas F
Pharmacol Ther; 2015 Jan; 145():43-57. PubMed ID: 25016186
[TBL] [Abstract][Full Text] [Related]
4. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.
Montgomery SA; Nielsen RZ; Poulsen LH; Häggström L
Hum Psychopharmacol; 2014 Sep; 29(5):470-82. PubMed ID: 25087600
[TBL] [Abstract][Full Text] [Related]
5. Vortioxetine for the treatment of depression.
Pearce EF; Murphy JA
Ann Pharmacother; 2014 Jun; 48(6):758-65. PubMed ID: 24676550
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacological properties of vortioxetine and its pre-clinical consequences].
David DJ; Tritschler L; Guilloux JP; Gardier AM; Sanchez C; Gaillard R
Encephale; 2016 Feb; 42(1 Suppl 1):1S12-23. PubMed ID: 26879252
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of vortioxetine for the treatment of major depressive disorder.
Dhir A; Sarvaiya J
Expert Rev Neurother; 2014 Dec; 14(12):1349-63. PubMed ID: 25418918
[TBL] [Abstract][Full Text] [Related]
8. [Vortioxetine in the treatment of major depression].
de Bartolomeis A; Fagiolini A; Maina G
Riv Psichiatr; 2016; 51(6):215-230. PubMed ID: 27996982
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
[TBL] [Abstract][Full Text] [Related]
10. Vortioxetine for the treatment of major depression.
Dhir A
Drugs Today (Barc); 2013 Dec; 49(12):781-90. PubMed ID: 24524096
[TBL] [Abstract][Full Text] [Related]
11. VORTIOXETINE - THE NEW ANTIDEPRESSANT AGENT WITH PROCOGNITIVE PROPERTIES.
Dziwota E; Olajossy M
Acta Pol Pharm; 2016 Nov; 73(6):1433-1437. PubMed ID: 29634095
[TBL] [Abstract][Full Text] [Related]
12. Vortioxetine: a New Treatment for Major Depressive Disorder.
Connolly KR; Thase ME
Expert Opin Pharmacother; 2016; 17(3):421-31. PubMed ID: 26679430
[TBL] [Abstract][Full Text] [Related]
13. Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant.
Sowa-Kućma M; Pańczyszyn-Trzewik P; Misztak P; Jaeschke RR; Sendek K; Styczeń K; Datka W; Koperny M
Pharmacol Rep; 2017 Aug; 69(4):595-601. PubMed ID: 28499187
[TBL] [Abstract][Full Text] [Related]
14. The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis.
Meeker AS; Herink MC; Haxby DG; Hartung DM
Syst Rev; 2015 Mar; 4():21. PubMed ID: 25874839
[TBL] [Abstract][Full Text] [Related]
15. New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine.
Orsolini L; Tomasetti C; Valchera A; Iasevoli F; Buonaguro EF; Vellante F; Fornaro M; Fiengo A; Mazza M; Vecchiotti R; Perna G; de Bartolomeis A; Martinotti G; Di Giannantonio M; De Berardis D
Expert Rev Neurother; 2016 May; 16(5):483-95. PubMed ID: 27050932
[TBL] [Abstract][Full Text] [Related]
16. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms.
Baldwin DS; Florea I; Jacobsen PL; Zhong W; Nomikos GG
J Affect Disord; 2016 Dec; 206():140-150. PubMed ID: 27474960
[TBL] [Abstract][Full Text] [Related]
17. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults.
Thase ME; Mahableshwarkar AR; Dragheim M; Loft H; Vieta E
Eur Neuropsychopharmacol; 2016 Jun; 26(6):979-93. PubMed ID: 27139079
[TBL] [Abstract][Full Text] [Related]
18. Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review.
De Diego-Adeliño J; Crespo JM; Mora F; Neyra A; Iborra P; Gutiérrez-Rojas L; Salonia SF
Expert Opin Drug Saf; 2022 May; 21(5):673-690. PubMed ID: 34964415
[TBL] [Abstract][Full Text] [Related]
19. Current and Future Perspectives on the Major Depressive Disorder: Focus on the New Multimodal Antidepressant Vortioxetine.
Orsolini L; Tomasetti C; Valchera A; Iasevoli F; Buonaguro EF; Fornaro M; Fiengo ALC; Martinotti G; Vellante F; Matarazzo I; Vecchiotti R; Perna G; Di Nicola M; Carano A; Di Bartolomeis A; De Giannantonio M; De Berardis D
CNS Neurol Disord Drug Targets; 2017; 16(1):65-92. PubMed ID: 27781949
[TBL] [Abstract][Full Text] [Related]
20. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study.
Baune BT; Sluth LB; Olsen CK
J Affect Disord; 2018 Mar; 229():421-428. PubMed ID: 29331703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]